Dx Deal Review Q3 2024
Leveraging Non-Invasive Testing in CNS and Endometriosis - Ongoing Research, Data Sharing
and AI Drive Diagnostic Innovations
Dx Deal Review Q3 2024
Download Request
Private Equity’s Path in European Specialty Pharma M&A: Mastering 2024’s Challenges and Seizing New Opportunities
The European specialty pharma M&A landscape is undergoing significant transformations, with private equity firms facing new and unprecedented challenges. This white paper examines the current state of private equity within the sector, identifying the key obstacles and trends reshaping investment strategies.
Private Equity’s Path in European Specialty Pharma M&A
Download Request
European Rare Disease M&A Activity in 2024
In 2024, the rare and orphan disease market has become a focal point for mergers and acquisitions (M&A) in the pharmaceutical industry.
Pharmaceutical companies are increasingly targeting this sector, driven by a combination of various incentives. This white paper explores the key factors driving M&A activity in the European rare disease space, and highlight notable deals and potential acquisition targets in 2024
European Rare Disease M&A Activity in 2024.
Download Request
How is AI changing drug discovery today and where will it go from here?
PharmaVentures Podcast Series, Edition 16
Listen as Adrian Dawkes talks to Kurt Herpel, CEO and Klaus Kratochwill, CSO of Delta 4, an Austrian /Swiss based AI tech company. Hear how their AI journey began more than 20 years ago and how the company developed into a key player in AI drug discovery. Hear how their clients are already benefiting from AI. You will hear their insights into;
- Where AI is benefiting drug discovery processes today?
- How will it be used in the future, will we get better drugs faster?
- Can it replace the need for human involvement?
- Will AI impact on the discovery and use of new biomarkers?
About the Presenter:
Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.
During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years' experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.
Pharma/Biotech M&A: Insights and Trends with Soren Demin
PharmaVentures Podcast Series, Edition 15
6990?i=1000636892027">
Listen as Soren Demin draws on his 20 years of M&A experience to provide insight into the current Pharma/Biotech M&A landscape. Key topics include;
- Is the M&A landscape recovering and will we see record activity again?
- How has the big pharma model changed and what is the impact on deal making?
- What is the direction of travel for deal volumes and values?
- How do biotechs position themselves to get the best deals?
- Who holds the upper hand, buyers or sellers?
- What does M&A look like for hot and emerging sectors such as AI drug discovery and Advanced Therapies?
To find out what the diagnostics deal making landscape looks like for you, you can request an initial complimentary consultation with the experts in this podcast via email: enquiries@pharmaventures.com
About the Interviewees:
Soren Demin is a Managing Director at PharmaVentures, where he excels in creating and unlocking value for clients through M&A, business development, and licensing. He joined PharmaVentures in 2024, bringing over 15 years of global experience in the biopharma industry.
Soren’s successful industry and investment banking career, combined with his advisory and medical background, is crucial for understanding clients’ needs and providing optimized solutions.
Before this role, Soren served as Chief Business Officer at the private equity-backed Essential Pharma. He also held the position of Commercial Director at the UK government’s biological manufacturing unit, Porton BioPharma, where he established new strategic collaborations and directed product development and manufacturing. Previously, Soren was part of Mitsubishi Tanabe and the Piramal Group
Soren began his M&A career at Goldman Sachs, focusing on cross-border deal origination across the US, MENA, Europe, and Asia, before which he studied for a Bachelor of Medicine at the University of Sheffield and a PhD in Biotechnology from the University of Cambridge.
About the Presenter:
Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.
During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years' experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.